Xiong Bo, Zhang Xinxin, Sangji Dongzhi, Ni Lianghong, Fan Mingjie, Fan Beibei
Department of Clinical Pharmacy, Baoshan Hospital Affiliated to, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Sci Rep. 2024 Dec 30;14(1):31567. doi: 10.1038/s41598-024-76063-z.
This study investigates the potential treatment of breast cancer utilizing Gentiana robusta King ex Hook. f. (QJ) through an integrated approach involving network pharmacology, molecular docking, and molecular dynamics simulation. Building upon prior research on QJ's chemical constituents, we conducted Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using the DAVID database. Network interactions and core genes were identified using Cytoscape 3.9.1. Key target genes, including Interleukin-6 (IL-6), tumour suppressor gene P53 (TP53), and epidermal growth factor receptor (EGFR), were selected for molecular docking with QJ's active components, 2'-O-β-D-glucopyranosyl-gentiopicroside and macrophylloside D, employing Schrodinger Maestro 13.5. Molecular dynamics (MD) simulations were performed using the Desmond program. A total of 270 intersection targets of active ingredients and diseases were identified, with three core targets determined through network topology screening. Enrichment analysis highlighted the involvement of QJ in breast cancer treatment, primarily through the hsa05200 cancer signaling pathway and the hsa04066 HIF-1 signaling pathway. Molecular docking and dynamics simulations demonstrated the close interaction of 2'-O-β-D-glucopyranosyl-gentiopicroside (QJ17) and macrophylloside D (QJ25) with IL6, TP53, and EGFR, and other target genes, showcasing a stabilizing effect. In conclusion, this study unveils the effective components and potential mechanisms of 2'-O-β-D-glucopyranosyl-gentiopicroside and macrophylloside D in breast cancer prevention and treatment. The identified components act on target genes such as IL6, TP53, and EGFR, regulating crucial pathways including the cancer signaling and Hypoxia-inducible factor 1 (HIF-1) signaling pathways. These findings provide valuable insights into the therapeutic potential of QJ in breast cancer management. However, further experimental research are needed to validate the computational findings of QJ.
本研究通过网络药理学、分子对接和分子动力学模拟等综合方法,探讨粗壮秦艽(Gentiana robusta King ex Hook. f.,QJ)对乳腺癌的潜在治疗作用。基于先前对QJ化学成分的研究,我们使用DAVID数据库进行了基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路分析。使用Cytoscape 3.9.1确定网络相互作用和核心基因。选择关键靶基因,包括白细胞介素-6(IL-6)、肿瘤抑制基因P53(TP53)和表皮生长因子受体(EGFR),与QJ的活性成分2'-O-β-D-吡喃葡萄糖基龙胆苦苷和大叶秦艽苷D进行分子对接,采用Schrodinger Maestro 13.5软件。使用Desmond程序进行分子动力学(MD)模拟。共鉴定出活性成分与疾病的270个交集靶点,通过网络拓扑筛选确定了三个核心靶点。富集分析突出了QJ在乳腺癌治疗中的作用,主要通过hsa05200癌症信号通路和hsa04066缺氧诱导因子1(HIF-1)信号通路。分子对接和动力学模拟表明,2'-O-β-D-吡喃葡萄糖基龙胆苦苷(QJ17)和大叶秦艽苷D(QJ25)与IL6、TP53和EGFR以及其他靶基因有紧密相互作用,显示出稳定作用。总之,本研究揭示了2'-O-β-D-吡喃葡萄糖基龙胆苦苷和大叶秦艽苷D在乳腺癌预防和治疗中的有效成分及潜在机制。所鉴定的成分作用于IL6、TP53和EGFR等靶基因,调节包括癌症信号通路和缺氧诱导因子1(HIF-1)信号通路在内的关键通路。这些发现为QJ在乳腺癌管理中的治疗潜力提供了有价值的见解。然而,需要进一步的实验研究来验证QJ的计算结果。